Benefits
Knee pain and daily function scores
In 139 adults aged 45 to 75 with mild to moderate knee osteoarthritis, one 250 mg capsule a day for 90 days lowered 100 mm knee pain scores by 14.4 mm versus 6.0 mm on placebo, and all five knee questionnaire scores, including daily activities and quality of life, improved more. The one trial was funded by the maker.
Knee discomfort and walking tests in adults with knee pain
In 96 healthy adults with chronic knee pain but no arthritis on X-ray, 250 mg a day for 90 days lowered pain after a fast 80 m walk by 1.5 versus 0.6 points on a 10 point scale, and walk and stair climb times improved more than on placebo. Knee bending range did not differ. The trial was funded by the maker and its manufacturing partner.
Blood markers of inflammation
In the 90 day trial in adults with knee osteoarthritis, hsCRP, TNF-alpha, IL-6 and IL-1beta, measured as secondary outcomes, fell more than on placebo. In the 90 day trial in adults with knee pain but no joint wear, changes in CRP, IL-6, TNF-alpha and MMP-3 did not differ from placebo. These are blood markers, not health outcomes, and both trials were maker-funded.
Muscle soreness after squat exercise
In 30 recreationally active adults, 250 mg a day for 29 days before and 4 days after a 15 minute squat session lowered soreness pain ratings over the next 96 hours compared with placebo, and serum LDH was lower. Creatine kinase, the standard muscle damage marker, did not differ, and no strength test was done. The one small trial was funded by the maker, and some of its reported ratings showed no spread at all.
Facial dark spot appearance and skin hydration
In 90 healthy women aged 18 to 40, 250 mg a day for 60 days reduced the darkness of one tracked facial dark spot, such as a sun spot or a mark left after a breakout, on 3D imaging and clinician grading more than placebo, a small absolute change (about 2 percent), and raised skin hydration and gloss. Skin tone evenness did not differ. The one trial was funded by the maker and its manufacturing partner.
Blood curcuminoid levels at a low dose
In two single-dose absorption studies run by the maker, the authors reported that one 250 mg capsule gave total curcuminoid exposure comparable to 1,500 mg of curcuminoids from a standard 95 percent extract or from an extract with piperine; the second study gives no statistics. Peak free curcumin did not differ from the standard extract. These are blood level markers, not health outcomes.
Mechanism of action
Water-dispersible format
The maker states that its proprietary process makes the curcuminoids disperse in water without piperine or synthetic carriers, and a patent listed by the trial authors describes curcuminoids melt-processed with maltodextrin and rice bran extract. In absorption studies total curcumin levels rose at a low dose, but an independent study of other products argues that absorption claims should rest on free curcumin, which stays at low levels in blood.
Curcuminoids and inflammatory signaling
In laboratory studies cited by the trial authors, curcuminoids lowered inflammatory messengers such as prostaglandin E2, nitric oxide, IL-6 and IL-8 and the cartilage-degrading enzymes MMP-1 and MMP-3. In people taking this extract, blood inflammation markers fell more than on placebo in one 90 day knee trial but did not differ in another, so the pathway is proposed rather than shown.
Proposed pain pathways after exercise
The muscle soreness trial authors propose that curcumin dampens the TRPV1 pain channel and the NF-kB and Nrf2 inflammatory pathways after exercise, citing earlier studies. Their trial measured pain ratings, questionnaires and two muscle enzymes but no inflammatory markers, so these steps were not tested with this extract.
Clinical trials
Randomized, double-blind, placebo-controlled parallel trial at two orthopedic centers in Varanasi, India; one 250 mg TurmXTRA 60N capsule (about 150 mg curcuminoids) daily after breakfast for 90 days versus an identical placebo, paracetamol allowed as rescue medication; registered CTRI/2023/07/055411; funded by Nutriventia and Laila Nutraceuticals; Shefali Thanawala and Rajat Shah are Nutriventia employees (Shah with ownership interests), two authors are Laila employees, and Thanawala, Shah and the two principal investigators report patents (including US11666535) issued to Nutriventia (Thanawala et al. 2025, J Pain Res)
140 adults aged 45 to 75 with knee osteoarthritis of Kellgren-Lawrence grade II or III and knee pain of 40 to 70 mm on a 100 mm scale (70 per group); 139 analyzed, mean age 56.
The VAS pain score, the primary outcome, fell by 14.41 mm on the extract versus 6.02 mm on placebo at day 90 (p < 0.0001), with a difference from day 7. At day 90 all five KOOS subscales improved more than on placebo, pain (17.7 versus 4.7 points), symptoms, daily activities, sport and recreation (p = 0.0323) and knee-related quality of life (p = 0.0087). hsCRP, TNF-alpha, IL-6 and IL-1beta fell more than on placebo at days 45 and 90 (p < 0.05 for each). One mild adverse event (abdominal pain) on the extract and three on placebo, all judged unrelated.
Randomized, double-blind, placebo-controlled parallel trial at three sites in Bangalore, India; one 250 mg capsule (150 mg curcuminoids) daily for 90 days versus an identical placebo; registered CTRI/2020/03/023877; funded by Inventia Healthcare (the 2022 trial lists Nutriventia as part of Inventia Healthcare) and Laila Nutraceuticals; Shefali Thanawala and Rajat Shah are Inventia employees, two authors are Laila employees and two are employees of the contract research organization; a 2023 erratum corrected a table value and a unit (Thanawala et al. 2021, Clin Pharmacol)
106 healthy adults aged 18 to 60 (mean age about 37) with knee pain for at least 2 months, pain of 4 or more out of 10, and no knee arthritis on X-ray (53 per group); 96 completed.
Pain on a 10 cm VAS after an 80 m fast walk, the primary outcome, fell by 1.5 versus 0.6 points (p < 0.0001); 55 versus 14 percent reached a 2 point fall. The 80 m walk (p = 0.0011) and 9 step stair climb (p < 0.0001) times improved more, although the median 80 m walk time stayed near 60 seconds in both groups; knee flexion did not differ (p = 0.3657). Changes in CRP, IL-6, TNF-alpha and MMP-3 did not differ between groups (p = 0.09 to 0.29). Three adverse events (headache and nausea on the extract, diarrhea on placebo) were judged unrelated, and liver tests did not change.
Randomized, double-blind, placebo-controlled parallel trial; one 250 mg TurmXTRA 60N capsule daily for 33 days, 29 days before and 4 days after 15 minutes of squats; registered CTRI/2021/12/038892; funded by Nutriventia, Inventia Healthcare; Shefali Thanawala and Rajat Shah are Nutriventia employees and two authors are employees of the contract research organization that ran the study (Thanawala et al. 2022, Evid Based Complement Alternat Med)
30 healthy, recreationally active adults aged 18 to 35 (21 men, 9 women; 15 per group); all completed.
Soreness pain on a 10 cm VAS (stated primary outcome: change from just after exercise to 96 hours) was lower on the extract at every time point from 12 hours (area under the curve 286.8 versus 460, p < 0.0001), for example 0.7 versus 3.3 at 96 hours. Well-being questionnaire scores and serum LDH (p = 0.0446, with one subject per group excluded from that analysis) also favored the extract, while creatine kinase did not differ. Several placebo ratings were reported with no variation at all (standard deviation 0), and the subjects' global ratings were 4.00 versus 2.00 with no spread in either group, an unusual pattern. No strength or performance test was done; no serious adverse events.
Randomized, double-blind, placebo-controlled parallel trial at one Mumbai skin research center; one 250 mg TurmXTRA 60N capsule daily for 60 days versus an identical placebo; registered CTRI/2024/06/068637; funded by Nutriventia and Laila Nutraceuticals; Shefali Thanawala and Rajat Shah are Nutriventia employees (Shah with ownership interests) and two authors are Laila employees (Thanawala et al. 2025, J Cosmet Dermatol)
96 healthy women aged 18 to 40 with one facial blemish, defined as a pigmented spot such as a dark mark left by a pimple or skin injury, an age spot or a sun spot, on otherwise healthy skin; severe acne excluded (48 per group); 90 completed.
The blemish reading on 3D imaging, the primary outcome, fell more than on placebo from day 30 (p = 0.036) to day 60 (p = 0.001), a small absolute change (64.4 to 62.9 units on the extract, a 2.3 versus 0.3 percent fall). Every participant was graded 3 of 4 on the clinician blemish scale at baseline. Clinician blemish grading, skin hydration, water loss through the skin and skin gloss also improved more than on placebo, while skin tone evenness did not differ. Mild bloating and diarrhea were reported by one participant each on the extract and six participants reported mild digestive complaints on placebo; one participant on the extract had an abnormal thyroid test at day 60, judged unrelated.
Open-label, randomized, two-way crossover, single oral dose pharmacokinetic study; one TurmXtra 60N capsule (150 mg curcuminoids) versus three capsules of a standard 95 percent turmeric extract (1,500 mg curcuminoids); authors from Inventia Healthcare, including Shefali Thanawala and Rajat Shah, Laila Nutraceuticals and Enem Nostrum; funding not stated in the abstract (Thanawala et al. 2021, J Pharm Pharmacol)
14 subjects.
Peak plasma levels of free curcumin, total curcuminoids, tetrahydrocurcumin and demethoxycurcumin did not differ despite the 10-fold lower curcuminoid dose. Peak total curcumin was higher on TurmXtra (43.5 versus 21.3 ng/mL, p = 0.0253), free curcumin exposure over time was higher (p < 0.001), and total curcumin and total curcuminoid exposure were comparable. These are blood level markers, not health outcomes. Five mild adverse events in three subjects were judged unrelated.
Open-label, randomized, two-period crossover pharmacokinetic study; one 250 mg capsule of the water-dispersible 60 percent extract (WDTE60N, the trial code for TurmXtra 60N in the other papers) versus three capsules of 500 mg curcuminoids with 5 mg piperine given 6 hours apart; no affiliations, funding or registration in the PubMed record, but Shefali Thanawala and Rajat Shah are Nutriventia employees in the group's other papers (Thanawala et al. 2024, Altern Ther Health Med)
16 healthy adult men, fasted overnight.
Geometric mean peak total curcuminoids were 74.56 ng/mL on the test capsule versus 22.75 ng/mL on the piperine product, and 24 hour exposure was 419.00 versus 359.86 h ng/mL, which the authors call equivalent exposure at a 10-fold lower curcuminoid dose. The abstract gives no p values or free curcumin results. These are blood level markers, not health outcomes.